235TiP - A Phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Breast Cancer, Locally Advanced
Breast Cancer, Metastatic
Breast Cancer
Presenter Aleix Prat
Citation Annals of Oncology (2017) 28 (suppl_5): v68-v73. 10.1093/annonc/mdx364
Authors A. Prat1, D. Yee2, M.P. Sablin3, H. Iwata4, E.L. Johnston5, T. Bogenrieder6, J. Serra7, K. Stucke-Straub8, P. Lo Russo9
  • 1Medical Oncology , Hospital Clínic, 8036 - Barcelona/ES
  • 2Medicine, Masonic Cancer Center, University of Minnesota, 55455 - Minnesota/US
  • 3Medical Oncology, Institut Curie, Paris/FR
  • 4Breast Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 5Oncology, Eli Lilly and Company, Indianapolis/US
  • 6Oncology, Boehringer Ingelheim RCV, Vienna/AT
  • 7Oncology, Boehringer Ingelheim España, S.A., Barcelona/ES
  • 8Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/DE
  • 9Medical Oncology, Yale Cancer Center, New Haven, Connecticut/US

Abstract

Background

The insulin-like growth factor (IGF) and the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathways have been implicated in the pathogenesis and resistance mechanisms of a variety of cancers, including HR+ HER2- BC and NSCLC. IGF-ligand dependent signalling via the IGF receptor results in upregulation of cyclin D1, and thus, progression through the cell cycle, providing rationale for the simultaneous inhibition of IGF and CDK4/6. This trial assesses the maximum-tolerated dose (MTD), safety and preliminary efficacy of the IGF ligand-neutralising antibody, xentuzumab, in combination with abemaciclib, a selective inhibitor of both CDK4 and 6, +/- hormone therapy, in pts with solid tumours.

Trial design

Study BI 1280.18 (NCT03099174) is a Phase Ib multicentre, non-randomised, open-label, dose escalation trial with four dose-finding cohorts (Cohorts A–D) followed by two expansion cohorts (Cohorts E, F). Eligible pts include adults ≥18 yrs (≥20 for Japan), with measurable or evaluable disease, adequate organ function, ECOG PS ≤ 1, and unresectable advanced or metastatic solid tumours after failure on standard therapy (Cohort A), postmenopausal locally advanced or metastatic HR+, HER2- BC (Cohorts B–D, F), or stage IV NSCLC after 1–2 lines of therapy and failure after platinum-based chemotherapy (Cohort E); CDK4/6 inhibitor-naïve pts (Cohorts A–E) and pts who have received prior CDK4/6 inhibitors (palbociclib or ribociclib) plus aromatase inhibitors (Cohort F) are included. Pts will receive either xentuzumab plus abemaciclib alone (Cohorts A, E) or in combination (at MTD defined for the doublet therapy) with letrozole (Cohort B), anastrozole (Cohort C), or fulvestrant (Cohorts D, F). Primary endpoints are the MTD and/or recommended phase-2-dose (RP2D; Cohorts A–D), and objective response (Cohorts E, F). Further endpoints include antitumour activity (Cohorts E, F), and pharmacokinetic outcomes (all Cohorts). This study will be conducted in the US, Europe and Japan. Pt screening is planned to start May 17; target enrolment: N≈88.

Clinical trial identification

NCT03099174; 1280.18

Legal entity responsible for the study

Boehringer Ingelheim

Funding

Boehringer Ingelheim

Disclosure

P. Lo Russo: Advisory boards: Agios: Data Safety Monitoring Board (2016-2017), Alexion: Advisory Board Member (2016-2017), Ariad: Advisory Board Member (2016-2017), GenMab: Advisory Board Member (2016-2017), Glenmark: Advisory Board Member (2016-2017), Halozyme: Data Safety Monitoring Board (2016-2017), Menarini: Advisory Board Member (2016-2017), Novartis: Advisory Board Member (2016-2017), Roche-Genentech: imCORE Alliance (2016-2019), Genentech: Advisory Board (2016-2017), CytomX: Advisory Board Member (2016-2017), Omniox: Advisory Board Member (2016-2017), Ignyta: Advisory Board Member (2016-2017). M.P. Sablin: Advisory board: Boehringer Ingelheim. E.L. Johnston: Employment: Eli Lilly and Company. Stock ownership or options: Eli Lilly and Company. T. Bogenrieder, J. Serra, K. Stucke-Straub: Employee of BI. All other authors have declared no conflicts of interest.